Acute administration of N-methyl-D-aspartate receptor (NMDAR) antagonists in healthy humans and animals produces working memory deficits similar to those observed in schizophrenia. However, it is unclear whether they also lead to altered low-frequency (≤60 Hz) neural oscillatory activities similar to those associated with schizophrenia during working memory processes. Here, we recorded local field potentials (LFPs) and single-unit activity from the lateral prefrontal cortex (LPFC) of three male rhesus macaque monkeys while they performed a rule-based prosaccade and antisaccade working memory task both before and after systemic injections of a subanesthetic dose (≤0.7 mg/kg) of ketamine. Accompanying working-memory impairment, ketamine enhan...
Following the discovery of the antidepressant properties of ketamine, there has been a recent resurg...
Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) recep...
Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine, provides a...
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has been implicated as a possible mechanis...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Alterations in the function of the medial prefrontal cortex (mPFC) and its major thalamic source of ...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
At subanaesthetic doses, ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has demonstra...
Ketamine is a dissociative anesthetic drug, which has more recently emerged as a rapid-acting antide...
Background: Working memory (WM) deficits are a core feature of schizophrenia. Electrophysiological s...
The World Health Organization has classified schizophrenia as one of the five leading causes of disa...
In humans, the effects of subanesthetic doses of ketamine, an N-methyl-d-aspartate (NMDA) receptor a...
International audienceIn prodromal and early schizophrenia, disorders of attention and perception ar...
Ketamine, an N-methyl-D-aspartate (NMDA) receptor glutamatergic antagonist, has been studied as a mo...
Following the discovery of the antidepressant properties of ketamine, there has been a recent resurg...
Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) recep...
Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine, provides a...
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has been implicated as a possible mechanis...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
Alterations in the function of the medial prefrontal cortex (mPFC) and its major thalamic source of ...
Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently implicated in the...
At subanaesthetic doses, ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has demonstra...
Ketamine is a dissociative anesthetic drug, which has more recently emerged as a rapid-acting antide...
Background: Working memory (WM) deficits are a core feature of schizophrenia. Electrophysiological s...
The World Health Organization has classified schizophrenia as one of the five leading causes of disa...
In humans, the effects of subanesthetic doses of ketamine, an N-methyl-d-aspartate (NMDA) receptor a...
International audienceIn prodromal and early schizophrenia, disorders of attention and perception ar...
Ketamine, an N-methyl-D-aspartate (NMDA) receptor glutamatergic antagonist, has been studied as a mo...
Following the discovery of the antidepressant properties of ketamine, there has been a recent resurg...
Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) recep...
Acute treatment with subanaesthetic doses of NMDA receptor antagonists, such as ketamine, provides a...